SciSparc Ltd (SPRC) Actualités

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

This innovative drug combination treatment focuses on boosting safety and efficacy in mental health and...

Form 425 - Prospectuses and communications, business combinations

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer

To date, SciSparc has advanced $4.25 million to Automax under the Bridge Loan agreement and amendments thereto...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacyin Mental Health and Addiction Treatments...

Form EFFECT - Notice of Effectiveness

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination

TEL AVIV, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc...

Form F-1 - Registration statement for certain foreign private issuers

SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million

SciSparc would be entitled to receive consideration valued at $3 million in Polyrizon securities, as well as...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]